| Dinu P Gangure, MD | |
|
Bjc Behavioral Health, 3165 Mckelvey Rd, Ste. 200, Bridgeton, MO 63044-2550 | |
| (314) 206-3900 | |
| Not Available |
| Full Name | Dinu P Gangure |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 27 Years |
| Location | Bjc Behavioral Health, 3165 Mckelvey Rd, Ste. 200, Bridgeton, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659335776 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 2002027109 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Westchester Medical Center Advanced Physician Services Pc | 3173660776 | 729 |
News Archive
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
In their research on eating disorders, Oregon Research Institute (ORI) scientists help young women reduce the influence of the "thin ideal," which is described as associating success and happiness with being thin.
› Verified 2 days ago
| Entity Name | Fw Of Saratoga Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386640084 PECOS PAC ID: 6305747049 Enrollment ID: O20040116000089 |
News Archive
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
In their research on eating disorders, Oregon Research Institute (ORI) scientists help young women reduce the influence of the "thin ideal," which is described as associating success and happiness with being thin.
› Verified 2 days ago
| Entity Name | Westchester Medical Center Advanced Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912131392 PECOS PAC ID: 3173660776 Enrollment ID: O20091031000042 |
News Archive
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
In their research on eating disorders, Oregon Research Institute (ORI) scientists help young women reduce the influence of the "thin ideal," which is described as associating success and happiness with being thin.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dinu P Gangure, MD 7225 Clayton Rd, Saint Louis, MO 63117-1506 Ph: (314) 517-3497 | Dinu P Gangure, MD Bjc Behavioral Health, 3165 Mckelvey Rd, Ste. 200, Bridgeton, MO 63044-2550 Ph: (314) 206-3900 |
News Archive
Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.
In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.
In their research on eating disorders, Oregon Research Institute (ORI) scientists help young women reduce the influence of the "thin ideal," which is described as associating success and happiness with being thin.
› Verified 2 days ago
Lawrence F. Kuhn, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 12277 De Paul Dr, Suite 303 South, Bridgeton, MO 63044 Phone: 314-344-7575 Fax: 314-344-7571 | |
Linda Shofner, CPNP Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 12303 De Paul Dr, Bridgeton, MO 63044 Phone: 314-344-6000 Fax: 314-344-6840 | |
Dr. Xinrong Lu, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12266 De Paul Dr Ste 100, Bridgeton, MO 63044 Phone: 314-738-2770 | |
Dr. Ellen Lockard Edens, MD, MPE, MA Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3165 Mckelvey Rd, Suite 200, Bridgeton, MO 63044 Phone: 314-206-3900 Fax: 314-206-3992 | |
Dr. Siddharth Kaul, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12266 De Paul Dr Ste 100, Bridgeton, MO 63044 Phone: 314-738-2770 | |
Dr. Amer Alshekhlee, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12266 De Paul Dr Ste 100, Bridgeton, MO 63044 Phone: 314-738-2770 | |
Dr. Daniel T Mattson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12266 De Paul Dr Ste 100, Bridgeton, MO 63044 Phone: 314-738-2770 |